Latest News on SDGR

Financial News Based On Company


Advertisement
Advertisement

Weekly Recap: ACV growth forecast and 75% hosted contracts by 2028

https://www.tradingview.com/news/tradingview:dfb78db646238:0-weekly-recap-acv-growth-forecast-and-75-hosted-contracts-by-2028/
Schrodinger, Inc. (NASDAQ:SDGR) projects its annual contract value (ACV) to increase by 12%–17% this year from $198 million, driven by demand across various sectors and new products. The company aims for 75% hosted contracts by 2028 and contributed two therapeutic programs to Tectora, which secured $55 million in funding. Analysts have also raised their average 12-month price target for SDGR shares to $33.57.

Schrodinger Eyes Growth From AI Assistant Bunsen and Hosted Software Shift

https://www.tradingview.com/news/marketbeat:1cb66f6c8094b:0-schrodinger-eyes-growth-from-ai-assistant-bunsen-and-hosted-software-shift/
Schrodinger (SDGR) plans to boost growth by expanding the use of its molecular discovery platform through its AI assistant, Bunsen, and a transition to hosted software contracts. The company expects a 12% to 17% increase in annual contract value (ACV) this year, driven by large pharmaceutical and life sciences customers, new products, and the growing materials science market. Bunsen, currently in beta, is intended to monetize through existing throughput-based licensing, making the platform accessible to a wider range of scientists, though the company notes it requires user expertise.

(SDGR) Movement as an Input in Quant Signal Sets

https://news.stocktradersdaily.com/news_release/14/SDGR_Movement_as_an_Input_in_Quant_Signal_Sets_111326122202_1794590522.html
This article provides an in-depth analysis of Schrodinger Inc. (NASDAQ: SDGR) using quantitative signals. It highlights strong sentiment supporting an overweight bias, outlines three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging), and details multi-timeframe signal analysis with support and resistance levels. The report emphasizes an exceptional risk-reward short setup and offers real-time analysis through the Stock Traders Daily PRO platform.

Form 144 SCHRODINGER INC For: 13 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-schrodinger-inc-for-13-november-93CH-5702274
This article announces the filing of Form 144 for SCHRODINGER INC (SDGR) on November 13, 2026. Form 144 is a notice of the intent to sell restricted stock. The article provides the title of the filing and its publication date.

Global software sales and marketing head Paul Jonathan Davie is an EVP at Schrodinger (SDGR).

https://www.stocktitan.net/sec-filings/SDGR/form-3-schrodinger-inc-initial-statement-of-beneficial-ownership-a197c7f60373.html
Schrodinger, Inc. (SDGR) has identified Paul Jonathan Davie as an officer, specifically as EVP, Chief Commercial Officer, and Global Head of Software Sales & Marketing, according to a Form 3 filing available on EDGAR. This initial statement of beneficial ownership indicates that Davie does not currently own any securities. The filing was accepted by the SEC on November 12, 2026, at 04:45 PM EST.
Advertisement

Form 144 SCHRODINGER INC For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-schrodinger-inc-for-13-november-93CH-4955997
Investing.com reported on November 13, 2026, about a Form 144 filing for SCHRODINGER INC (SDGR). The article notes that SCHRODINGER INC's stock experienced a -4.28% change. The content primarily states the filing's existence without providing further details on its specifics.

Schrodinger (SDGR) commercial chief also receives 18,400 restricted stock units.

https://www.stocktitan.net/sec-filings/SDGR/form-4-schrodinger-inc-insider-trading-activity-187e2f2a5757.html
Paul Jonathan Davie, EVP, Chief Commercial Officer, and Global Head of Software Sales & Marketing at Schrodinger, Inc. (SDGR), was granted 18,400 restricted stock units and options for 110,600 shares on November 11, 2026. The RSUs will vest in equal installments through July 2030, while the options, with an exercise price of $31.52, will vest quarterly, starting May 26, 2027, through May 2030, all subject to continued service. These equity awards are part of the company's 2022 Equity Incentive Plan.

Schrodinger Inc stock hits 52-week high at 33.83 USD

https://www.investing.com/news/company-news/schrodinger-inc-stock-hits-52week-high-at-3383-usd-93CH-5019247
Schrodinger Inc (SDGR) stock recently hit a 52-week high of $33.83, currently trading just 1% below this peak, reflecting an 84.2% increase over the past year and a 155% surge in the last six months. Despite strong financial results for Q3 2026, including a narrower loss and higher revenue than anticipated, InvestingPro analysis suggests the stock may be overvalued and volatile. The company's market capitalization stands at $2.52 billion, driven by robust software sales and drug discovery revenue.

Schrodinger Inc stock hits 52-week high at 33.83 USD By Investing.com

https://in.investing.com/news/stock-market-news/schrodinger-inc-stock-hits-52week-high-at-3383-usd-93CH-5697313
Schrodinger Inc (SDGR) stock reached a 52-week high of $33.83, currently trading at $33.84, reflecting an 84.2% increase over the past year and a 155% surge in six months. Despite this strong performance, InvestingPro analysis suggests the stock is overvalued and volatile. The company recently reported better-than-expected Q3 2026 financial results, with a narrower loss per share and higher revenue driven by strong software and drug discovery sales.

Schrodinger, Inc. Stock 12‑Month Price Target Raised to $33.57, Implies 1% Upside

https://www.tradingview.com/news/tradingview:950cec6b6e03f:0-schrodinger-inc-stock-12-month-price-target-raised-to-33-57-implies-1-upside/
The average 12-month price target for Schrodinger, Inc. (SDGR) stock has been raised from $31.14 to $33.57 by 7 analysts, suggesting a 1% potential upside from its November 9 closing price. The consensus rating for the stock remains a "Buy," with 5 buy ratings and 2 hold ratings among covering analysts.
Advertisement

Form 144 SCHRODINGER INC For: 10 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-schrodinger-inc-for-10-november-93CH-5692577
Investing.com reported on a Form 144 filing for SCHRODINGER INC, dated November 10. This type of filing indicates an insider's intent to sell restricted or controlled securities. The article provides the basic announcement without further details on the transaction.

Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry

https://batteriesnews.com/schrodinger-research-published-in-nature-reveals-new-insights-into-lithium-ion-battery-chemistry/
Schrödinger, Inc. announced the publication of new research in Nature revealing critical insights into lithium-ion battery (LIB) electrolytes. The study, in collaboration with Columbia University and the New York Structural Biology Center, discovered multi-lithium ion clustering, challenging previous assumptions and offering a path toward predictive battery design. These findings, achieved using Schrödinger's physics-powered computational platform, could lead to higher-capacity, faster-charging, and longer-lasting batteries.

Schrödinger, Inc. (SDGR) Seasonal returns chart

https://au.finance.yahoo.com/quote/SDGR/seasonality/
This article provides a historical seasonality chart for Schrödinger, Inc. (SDGR), displaying the average monthly price return between 2020 and 2026. It also includes current stock performance data and links to various financial metrics for the company.

Schrödinger raises 2026 ACV and drug discovery outlook as Q3 revenue rises 19% to $64.5 million; net loss widens to $37.7 million

https://mlq.ai/news/schrodinger-raises-2026-acv-and-drug-discovery-outlook-as-q3-revenue-rises-19-to-645-million-net-loss-widens-to-377-million/
Schrödinger (SDGR) reported a 19% increase in Q3 2026 revenue to $64.5 million, leading the company to raise its full-year 2026 guidance for annual contract value (ACV) and drug discovery revenue. Despite the revenue growth and a narrowed operating loss, the net loss widened to $37.7 million primarily due to a drop in the fair value of equity investments. The company highlighted strong software revenue, particularly from hosted software, and significant progress in its drug discovery pipeline through milestone payments and strategic contributions.

Schrodinger, Inc. Stock 12‑Month Price Target Raised to $29, Implies 2% Upside

https://www.tradingview.com/news/tradingview:84ab03855ec08:0-schrodinger-inc-stock-12-month-price-target-raised-to-29-implies-2-upside/
The average 12-month price target for Schrodinger, Inc. (SDGR) stock has been raised from $25.86 to $29 by 7 analysts, with forecasts ranging from $20 to $36 per share. This updated target implies a potential upside of approximately 2% based on the Nov. 4 closing price. The consensus rating for the stock remains a "Buy," with 5 analysts recommending Buy and 2 recommending Hold.
Advertisement

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates

https://uk.finance.yahoo.com/news/schrodinger-inc-sdgr-reports-q3-234521526.html
Schrodinger, Inc. (SDGR) reported a Q3 loss of $0.5 per share, which was better than the Zacks Consensus Estimate of a $0.66 loss. The company also surpassed revenue estimates, posting $64.49 million against an expectation of $40.15 million, leading to a 40.15% surprise. Schrodinger's stock has seen a significant gain of 52% year-to-date, outperforming the S&P 500.

Schrodinger Inc (SDGR) (Q3 2026) Earnings Call Highlights: Raised Guidance and Strong ACV ...

https://sg.finance.yahoo.com/news/schrodinger-inc-sdgr-q3-2026-051749755.html
Schrodinger Inc. (SDGR) reported strong Q3 2026 earnings, with ACV up 17% year-over-year and total revenue increasing by 19% to $64.5 million. The company raised its full-year 2026 ACV guidance to $222-$232 million and drug discovery revenue guidance to $75-$85 million, driven by a milestone payment from Structure's oral amylin program. Despite a widened net loss of $38 million, the company demonstrated disciplined expense management and a strong cash position of $373 million.

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates

https://sg.finance.yahoo.com/news/schrodinger-inc-sdgr-reports-q3-234521526.html
Schrodinger, Inc. (SDGR) reported a Q3 loss of $0.50 per share, which beat the Zacks Consensus Estimate of a $0.66 loss, and exceeded revenue estimates with $64.49 million. The company has surpassed EPS estimates three times and revenue estimates three times over the last four quarters. Despite outperforming the market year-to-date, the stock currently holds a Zacks Rank #3 (Hold).

Schrodinger Inc. (SDGR) Tops Q3 EPS by 19c

https://www.streetinsider.com/Earnings/Schrodinger+Inc.+%28SDGR%29+Tops+Q3+EPS+by+19c/27290731.html
Schrodinger Inc. (NASDAQ: SDGR) reported its Q3 earnings, surpassing analyst estimates for EPS by $0.19 with a reported loss of ($0.50) per share against an expected ($0.69). The company also exceeded revenue expectations, bringing in $64.49 million compared to the consensus estimate of $47.67 million.

Schrodinger Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62896993/schrodinger-q3-2026-earnings-call-transcript
Schrodinger (NASDAQ: SDGR) reported strong third-quarter 2026 results, with ACV growing 17% year-over-year, driven by increased adoption in pharmaceutical and materials science sectors. The company introduced Bunsen, an AI co-scientist, which now manages 80% of internal high-throughput calculations and is showing promising customer engagement. Full-year guidance for ACV and drug discovery revenue was raised, reflecting continued momentum and successful advancements in both software and therapeutics portfolios, including the launch of Tectora, a new co-founded company.
Advertisement

Schrodinger faces earnings test after Q2 surprise profit By Investing.com

https://uk.investing.com/news/stock-market-news/schrodinger-faces-earnings-test-after-q2-surprise-profit-93CH-4957406
Schrodinger Inc. is set to announce its third-quarter results, with analysts anticipating a loss after a surprise profit in Q2. Investors will be scrutinizing the company's core software business, the stability of its drug-discovery collaboration revenue, and its path to sustained profitability, especially given its recent foray into AI tools for drug discovery.

Price-Driven Insight from (SDGR) for Rule-Based Strategy

https://news.stocktradersdaily.com/news_release/24/Price-Driven_Insight_from_SDGR_for_Rule-Based_Strategy_110326123801_1793727481.html
This article provides a price-driven insight into Schrodinger Inc. (NASDAQ: SDGR) for rule-based trading strategies, highlighting strong sentiment across all horizons and an exceptional short setup. It outlines specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses, along with a multi-timeframe signal analysis. The report, generated by AI models, emphasizes risk management and offers real-time signals and analysis for subscribers.

Schrödinger, Inc. (SDGR) Seasonal returns chart

https://uk.finance.yahoo.com/quote/SDGR/seasonality/
The article provides a brief overview of Schrödinger, Inc. (SDGR), noting its stock price movement and upcoming Q3 2026 earnings call. It mentions that seasonality data for SDGR is currently unavailable. The page also displays general market information and trending tickers.

Schrödinger, Inc. (SDGR) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/SDGR/seasonality/
The article provides a seasonal returns chart for Schrödinger, Inc. (SDGR), displaying the average monthly price return from 2020 to 2026. It also includes current stock performance data, showing SDGR at 27.14 USD, a decrease of 9.50% at market close on October 30.

Schrödinger Surges 13.2% Amid Sector-Wide Rally

https://news.alphastreet.com/schrodinger-surges-13-2-amid-sector-wide-rally/
Schrödinger shares surged 13.2% on Wednesday, reaching $30.25 on heavy volume, driven by a broad rally across the health information services sector. This outsized gain, amidst peers like CERT and TDOC also advancing, suggests increased investor interest in computational drug discovery platforms. Investors are advised to monitor sustained sector momentum and any company-specific announcements from Schrödinger.
Advertisement

Schrodinger Inc. Company & People | SDGR

https://www.barrons.com/market-data/stocks/sdgr/company-people?amp%252525252525253Bmod=searchbar&mod=quotes&%25252525252525253Bmod=searchbar
This page provides a comprehensive overview of Schrodinger Inc. (SDGR), including its stock performance, key financials, analyst ratings, and company details. Schrodinger Inc. specializes in chemical simulation software solutions for the pharmaceutical and materials science industries, operating through Software and Drug Discovery segments. The company's leadership, valuation, profitability, efficiency, capitalization, and liquidity metrics are also detailed.

Schrödinger to Present at UBS Global Healthcare Conference

https://www.01net.it/schrodinger-to-present-at-ubs-global-healthcare-conference/
Schrödinger, Inc. (Nasdaq: SDGR) announced that its management will participate in a fireside chat at the UBS Global Healthcare Conference. The presentation is scheduled for Tuesday, November 10, 2026, at 9:30 a.m. E.T. A live webcast of the event will be available on Schrödinger’s website, with an archive accessible for approximately 90 days.

Schrodinger Inc. Financials | SDGR

https://www.barrons.com/market-data/stocks/sdgr/financials?amp%252525252525253Bmod=searchbar&mod=quotes&%25252525252525253Bmod=searchbar
This article provides a comprehensive financial overview of Schrodinger Inc. (SDGR), detailing its stock performance, key financial metrics, and a full income statement for several fiscal years. It also includes analyst ratings, company profile information, and comparisons with peer companies. The data aims to offer investors a detailed look at the company's financial health and market position.

SDGR | Schrodinger Inc. Stock Overview (U.S.: Nasdaq)

https://www.barrons.com/market-data/stocks/sdgr?amp%25252525253Bsearch_statement_type=suggested&%252525252525253Bmod=searchbar&%25252525252525253Bmod=searchbar&mod=quotes
This article provides an overview of Schrodinger Inc. (SDGR) stock, detailing its Nasdaq listing, current market data, analyst ratings, and financial performance. It includes key company information such as market value, EPS, and short interest, alongside major institutional holders and financial statements from 2025.

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.financialcontent.com/article/bizwire-2026-10-26-schrdinger-reports-inducement-grants-under-nasdaq-listing-rule-5635c4
Schrödinger, Inc. reported granting restricted stock units (RSUs) for 5,716 shares to five newly hired employees on October 21, 2026. These grants were made under the company’s 2021 Inducement Equity Incentive Plan, approved by the compensation committee, and served as a material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% after 12 months and the remainder in equal yearly installments over the subsequent three years.
Advertisement

Schrodinger, Inc. (SDGR) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_6127_QuantitativeReport_1792540800000
Argus has lowered its target price for Schrodinger Inc. (SDGR) to $25.00, with the current price standing at $23.80. Schrodinger Inc. operates as a healthcare-based software company with segments in Software and Drug discovery. The report was published on October 21, 2026.

Schrodinger, Inc. Estimates – NASDAQ:SDGR

https://www.tradingview.com/symbols/NASDAQ-SDGR/financials-estimates/
This article provides an overview of Schrodinger, Inc. (NASDAQ: SDGR) on TradingView, focusing on its financial estimates. Users can explore reported financial data and analyst estimates for the income statement, balance sheet, cash flow statement, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform explicitly states that the content is not investment advice and encourages users to conduct their own research.

Schrodinger, Inc. Estimates – GETTEX:43Z

https://www.tradingview.com/symbols/GETTEX-43Z/financials-estimates/
This article provides an overview of Schrodinger, Inc. (GETTEX:43Z) financial estimates and actuals, accessible through TradingView. Users can explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The platform allows comparison of actual results with average, high, and low estimates for the company.

Is Schrödinger (SDGR) Fairly Valued Following Its Nature Battery Research?

https://simplywall.st/stocks/us/healthcare/nasdaq-sdgr/schrodinger/news/is-schrdinger-sdgr-fairly-valued-following-its-nature-batter
Schrödinger (SDGR) recently published new research in Nature on lithium-ion battery electrolytes, leading to a cautious market reaction despite strong short-term gains. While some narratives suggest the stock is slightly overvalued at $22.60, a Discounted Cash Flow (DCF) model indicates it could be significantly undervalued, trading about 46% below an estimated fair value of $41.70. Investors are now tasked with evaluating which valuation framework more accurately reflects Schrödinger's future prospects.

Schrodinger Inc. Research & Ratings | SDGR

https://www.barrons.com/market-data/stocks/sdgr/research-ratings?%2525253Bmod=searchbar&%2525252525252525253Bmod=searchbar
This article provides a detailed overview of Schrodinger Inc. (SDGR) research and ratings. It includes analyst ratings, stock grader assessment, financial data, yearly and quarterly earnings estimates, and a company profile. The consensus among analysts is a "Buy" with an average price target of $25.86.
Advertisement

Schrödinger to Announce Third Quarter 2026 Financial Results on November 4

https://finance.yahoo.com/markets/stocks/articles/schr-dinger-announce-third-quarter-123000120.html
Schrödinger, Inc. (Nasdaq: SDGR) will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market closes. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss the results. The live webcast will be available on Schrödinger's website in the "Investors" section.

Schrödinger to Announce Third Quarter 2026 Financial Results on November 4

https://www.financialcontent.com/article/bizwire-2026-10-21-schrdinger-to-announce-third-quarter-2026-financial-results-on-november-4
Schrödinger, Inc. (Nasdaq: SDGR) announced it will report its third-quarter 2026 financial results on Wednesday, November 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results. The live webcast will be accessible in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days.

TD Cowen raises target for Schrodinger stock to USD 31.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/td-cowen-raises-target-for-schrodinger-stock-to-usd-31-00/70377763
TD Cowen has raised its price target for Schrodinger (SDGR) stock from USD 20.00 to USD 31.00, maintaining a Buy rating. This new target is significantly above the recent analyst consensus and the current Nasdaq price. The company's valuation is heavily dependent on its software growth, drug-development progress, and future earnings potential rather than current net income.

SDGR Maintained by UBS -- Price Target Raised to $21.00

https://www.gurufocus.com/news/9131825/sdgr-maintained-by-ubs-price-target-raised-to-2100
UBS analyst Kevin Caliendo maintained a Neutral rating for Schrodinger (SDGR) but raised the price target from $19.00 to $21.00. While the stock appears undervalued by 3.5% according to GuruFocus's GF Value™, concerns remain regarding its profitability challenges and significant insider selling, leading to a cautious outlook despite growth potential.

UBS Adjusts Schrodinger Price Target to $21 From $19, Maintains Neutral Rating

https://finance.yahoo.com/markets/stocks/articles/ubs-adjusts-schrodinger-price-target-140908690.html
UBS has adjusted its price target for Schrodinger (SDGR) to $21, up from the previous $19, while maintaining a Neutral rating on the stock. The company currently holds an average analyst rating of "overweight" with a mean price target of $21.43. Access to the full MT Newswires article requires a premium subscription.
Advertisement

Schrödinger Stock In Focus After Battery Electrolyte Study In Nature

https://simplywall.st/stocks/us/healthcare/nasdaq-sdgr/schrodinger/news/schrdinger-stock-in-focus-after-battery-electrolyte-study-in
Schrödinger, Inc. recently had research published in Nature, detailing how its computational platform was used to map lithium-ion battery electrolytes at an atomic scale, identifying multi-lithium ion complexes that influence electrolyte behavior. This study could impact the demand for Schrödinger's materials-focused software and collaboration opportunities. While the research supports the company's broader thesis of applying its physics-based platform to scientific problems beyond drug discovery, the near-term investment narrative still heavily relies on execution in its core pharma and biotech sectors and managing cost pressures.

Schrödinger Stock In Focus After Battery Electrolyte Study In Nature

https://simplywall.st/stocks/us/healthcare/nasdaq-sdgr/schrodinger/news/schrdinger-stock-in-focus-after-battery-electrolyte-study-in/amp
Schrödinger, Inc. announced a research publication in Nature, detailing how its computational platform was used to map lithium-ion battery electrolytes at an atomic scale, identifying multi-lithium ion complexes that affect battery behavior. This study could significantly impact the design of next-generation battery electrolytes, potentially increasing demand for Schrödinger's materials-focused software and expanding its collaboration pipeline. While supporting the company's broader thesis in scientific problem-solving, the near-term financial outlook remains tied to execution in pharma and biotech, managing costs, and achieving profitability.

Schrodinger stock fell 11.30 percent on October 16, 2026, 33.10 percent below high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/schrodinger-stock-fell-11-30-percent-on-october-16-2026-33-10-percent/70350033
Schrodinger stock experienced a significant drop of 11.30 percent on October 16, 2026, closing at USD 22.60, and is now 33.10 percent below its 52-week high. The company's market capitalization stands at USD 1.7 billion, and its trailing P/E ratio is a negative 30.54, indicating loss-based valuation. Investors are looking forward to the third-quarter results on November 11, 2026, which will be a key indicator for assessing its software and drug-discovery businesses.

TD Cowen lifts target for Schrödinger stock to USD 31.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/td-cowen-lifts-target-for-schroedinger-stock-to-usd-31-00/70333021
TD Cowen has raised its price target for Schrödinger (SDGR) stock to $31.00 from $20.00, citing the company's platform combining molecular discovery software with drug-discovery operations. Schrödinger's stock has seen a 40.10% year-to-date gain, with its market capitalization at $1.9 billion. The company is expected to report its third-quarter results on November 4, 2026.

How Schrodinger Inc. (SDGR) Affects Rotational Strategy Timing

https://news.stocktradersdaily.com/news_release/141/How_Schrodinger_Inc._SDGR_Affects_Rotational_Strategy_Timing_101426033401_1791963241.html
This article analyzes Schrodinger Inc. (SDGR) using AI models to provide institutional trading strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, identifying resistance and support levels. The report offers specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies, emphasizing risk management.
Advertisement

TD Cowen Maintains Schrodinger(SDGR.US) With Buy Rating, Raises Target Price to $31

https://www.moomoo.com/news/post/1001048603/td-cowen-maintains-schrodinger-sdgrus-with-buy-rating-raises-target
TD Cowen has reiterated its Buy rating for Schrodinger (SDGR.US) and increased the price target to $31. This update reflects the firm's continued confidence in the company's prospects.

SDGR Maintained by BMO Capital -- Price Target Raised to $30.00

https://www.gurufocus.com/news/9119693/sdgr-maintained-by-bmo-capital-price-target-raised-to-3000
BMO Capital analyst Gary Nachman maintained an "Outperform" rating for Schrodinger (SDGR) and raised the price target from $24.00 to $30.00. While the analyst rating is positive, GuruFocus indicates that SDGR is currently 6.9% overvalued based on its GF Value™ of $24.05 compared to its current price of $25.71, and there has been notable insider selling activity. The company has a GF Score™ of 72/100, showing strong momentum and growth potential, but faces challenges in profitability.

Schrodinger Inc (SDGR) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 72/100

https://www.gurufocus.com/news/9118182/schrodinger-inc-sdgr-stock-up-34-but-gf-value-says-overvalued-gf-score-72100
Schrodinger Inc (SDGR) stock rose 3.4% to $27.28, but its GF Value of $24.08 indicates it is 13.3% overvalued. Despite a strong GF Score of 72/100, driven by a perfect momentum rank, the company faces profitability challenges (3/10) and insider selling of $2.3 million with no buying activity. Investors are advised to exercise caution due to the overvaluation and mixed signals from insiders and gurus.

Schrodinger, Inc. (SDGR) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_6127_QuantitativeReport_1791331200000
Schrodinger, Inc. (SDGR) is a healthcare-based software company with segments in Software and Drug Discovery. Argus has lowered its price target for SDGR to $30.00, while the current price is $27.28. The article mentions an option to upgrade for exclusive reports and trade insights.

Schrödinger, Inc. (SDGR) Options Chain

https://ca.finance.yahoo.com/quote/SDGR/options/?date=1818720000&straddle=false&type=all
This page provides detailed options chain data for Schrödinger, Inc. (SDGR) for the August 20, 2027 expiration date. It lists various call and put options, including strike prices, last trade dates, last prices, and implied volatility. The current stock price and recent trading activity for SDGR are also displayed.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement